BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor

Reuters11-13

Nov 13 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:

X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COMPLETED SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA $(CN)$
X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN ABSOLUTE NEUTROPHIL COUNTS
X4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN G-CSF DOSING WHILE MAINTAINING ANC
X4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Source text: nGNX9zwzFh

Further company coverage: XFOR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483001793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-13 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483001793","market":"us","top_or_hot":-1,"title":"BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor </title></head><body><p><span>Nov 13 (Reuters)</span><span> - </span>X4 Pharmaceuticals Inc <span>XFOR.O</span>:</p><ul><li><p>X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COMPLETED SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA <a href=\"https://laohu8.com/S/CN\">$(CN)$</a></p></li><li><p>X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN ABSOLUTE NEUTROPHIL COUNTS</p></li><li><p>X4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN G-CSF DOSING WHILE MAINTAINING ANC</p></li><li><p>X4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>nGNX9zwzFh</span></p><p>Further company coverage: <span>XFOR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor Nov 13 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3JLYVG:1","article_id":"2483001793","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483001793","pubTimestamp":1731501514,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor Nov 13  - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COMPLETED SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN ABSOLUTE NEUTROPHIL COUNTSX4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN G-CSF DOSING WHILE MAINTAINING ANCX4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTSSource text: nGNX9zwzFhFurther company coverage: XFOR.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XFOR":"X4制药"},"translate_title":"BRIEF-X4 Pharmaceuticals报告已完成为期六个月的mavorixafor 2期试验的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XFOR":0.9},"content_text":"BRIEF-X4 Pharmaceuticals reports positive results from completed six-month phase 2 trial of Mavorixafor Nov 13 (Reuters) - X4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COMPLETED SIX-MONTH PHASE 2 TRIAL OF MAVORIXAFOR IN CHRONIC NEUTROPENIA $(CN)$X4 PHARMACEUTICALS- MAVORIXAFOR DURABLY ELEVATES MEAN ABSOLUTE NEUTROPHIL COUNTSX4 PHARMACEUTICALS INC - MAVORIXAFOR ENABLES REDUCTIONS IN G-CSF DOSING WHILE MAINTAINING ANCX4 PHARMACEUTICALS INC - MAVORIXAFOR WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTSSource text: nGNX9zwzFhFurther company coverage: XFOR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483001793"}